BLB-201A Study of BLB-201 RSV Vaccine in Infants and Children

Sponsor:

Blue Lake Biotechnology Inc.

Code:

NCT05655182

Conditions

Respiratory Syncytial Virus Infections

Eligibility Criteria

Sex: All

Age: 0 - 5

Healthy Volunteers: Accepted

Interventions

PIV5-vectored RSV Vaccine (BLB-201) Low Dose

PIV5-vectored RSV Vaccine (BLB-201) High Dose

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Blue Lake Biotechnology Inc. on 2026-07-29.